Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy
Authors:
- Lambers HeerspinkLHLambers Heerspink
- H. J.HJH. J.
- M. J. FowlerMFM. J. Fowler
- J. VolgiJVJ. Volgi
- A. T. ReutensARA. T. Reutens
- I. KleinIKI. Klein
- T. A. HerskovitsTHT. A. Herskovits
- D. K. PackhamDPD. K. Packham
- I. R. FraserIFI. R. Fraser
- S. L. SchwartzSSS. L. Schwartz
- C. AbaterussoCAC. Abaterusso
- J. LewisJLJ. Lewis
- 18 October 2007
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 24 (11) , 1290-1295
Abstract
Background Patients with Type 2 diabetes and albuminuria are at high risk to progress to end‐stage renal disease (ESRD). Although angiotensin receptor blockers confer renoprotection, many diabetic patients still develop overt nephropathy and reach ESRD. Glycosaminoglycans belong to the same family as heparin and heparinoids. Pilot studies with sulodexide, a glycosaminoglycan, have shown that sulodexide can reduce urinary albumin excretion rates in diabetic patients. No hard renal end‐point data are available.Methods Two multicentre, double‐masked, randomized placebo controlled trials were designed to study the renoprotective potential of sulodexide. The Sulodexide Microalbuminuria Trial examined the efficacy of sulodexide given over 26 weeks in 1000 patients with Type 2 diabetes, hypertension and microalbuminuria. The Sulodexide Overt Nephropathy Trial examined the efficacy of sulodexide in 2240 patients with Type 2 diabetes, hypertension and proteinuria ≥ 900 mg/24 h.Results The primary outcome of The Sulodexide Microalbuminuria Trial was (i) conversion to normoalbuminuria and at least a 25% decrease in the urinary albumin creatinine ratio (UACR), or (ii) at least a 50% reduction in UACR. The primary outcome of The Sulodexide Overt Nephropathy Trial was time to a composite end point of doubling of serum creatinine or ESRD.Conclusions The sulodexide nephropathy programme will document whether therapy with sulodexide confers renal protection in Type 2 diabetes and nephropathy.Keywords
This publication has 21 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2007Diabetes Care, 2007
- Heparanase-1 Gene Expression and Regulation by High Glucose in Renal Epithelial CellsDiabetes, 2005
- Preventing Microalbuminuria in Type 2 DiabetesNew England Journal of Medicine, 2004
- Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAALKidney International, 2004
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Effect of suiphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathyNephrology Dialysis Transplantation, 1996
- Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitusThe Lancet, 1995
- The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic NephropathyNew England Journal of Medicine, 1993